Hey Goose,

Not for nothing, but I've been here since February of 2019 as an investor and was officially registered here in March of 2020, and over that time it has been clear to me that going at it alone wasn't really the goal. As time went on it did seem the solo route gained some traction as a possibility but they've never stopped referencing partners, and along the way there's been fairly consistent throwaway lines in calls where he holds our current and future status up against companies that have been acquired. Like the "no company has ever had two BTD's and not gotten acquired" line. That's not saying "we're about to have two BTD's and be the first to refuse a buyout". It's saying "hey guys, look at where we sit? If we can get to two BTD's big pharma is going to come knocking".

Along that same line he's always bragging about the talks we're in with big pharma and how they want to see the data as soon as it's unblinded. So I think it's just a matter of perspective from us investors. We all read the tea leaves differently, but I just don't see nearly as much historical narrative around going at it alone as I do discussion about partners and buyouts. Obviously he wouldn't want to accept a buyout that wasn't representative of all that LL has to offer, which is great for us because that number will be a large one. But that doesn't automatically mean he wouldn't sell out for the right offer, or even one that's more realistic for whatever stage we're in when it comes.

I'd love it if we grew to a gigantic pharma company all on our own. It would be ideal from a return on our investment. But at this point I feel pretty confident in saying that I don't believe it's going to happen. We'll have some sort of partner(s). I will, however, say that I think if this all shakes out right I think we'll have just a single big pharma partner and everything else will grow from within Cytodyn. Which is the next best thing, I suppose.